Global Herpes Treatment Market to Grow by $ 677 Million During 2020-2024 | Highlights Key Segments and Regions of Growth | Technavio

The herpes treatment market is expected to grow by USD 677.02 million, progressing at a CAGR of almost 4% during the forecast period.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005053/en/

Technavio has announced its latest market research report titled Global Herpes Treatment Market 2020-2024 (Graphic: Business Wire)

For a More Detailed Analysis, Get a Free Sample Report Delivered Instantly

The increasing prevalence of herpes infection is one of the major factors propelling the market growth. However, factors such as the highly genericized market will hamper growth.

More details: https://www.technavio.com/talk-to-us?report=IRTNTR44343

Herpes Treatment Market: Type Landscape

Based on the type, the market saw maximum growth in the herpes zoster segment in 2019. This is due to the rising prevalence rate of herpes zoster and expected drug launches for the treatment of the condition. Also, factors such as the rising number of immunocompromised people and the increasing older population are contributing to the growth of the segment. The market growth in the segment will be significant over the forecast period.

Herpes Treatment Market: Geographic Landscape

By geography, Asia is going to have a lucrative growth during the forecast period. About 38% of the market’s overall growth is expected to originate from Asia. Factors such as the high prevalence rate of herpes infection, increased awareness, and entry of new players are fostering the growth of the herpes treatment market in Asia.

Japan is the key market for herpes treatment in Asia. Market growth in this region will be faster than the growth of the market in other regions.

Develop Smart Strategies for Your Business: Get a Free Sample Report Now!

Related Reports on Health Care Include:

Global Shingles Vaccine Market - Global shingles vaccine market is segmented by type (recombinant vaccines and live-attenuated vaccines) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Global Bone Cancer Drugs Market - Global bone cancer drugs market is segmented by indication (osteosarcoma, Ewing's sarcoma, chondrosarcoma, and other bone cancers) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Companies Covered:

• Bausch Health Companies Inc.

• Cipla Inc.

• Eli Lilly and Co.

• Gilead Sciences Inc.

• GlaxoSmithKline Plc

• Maruho Co. Ltd.

• Merck & Co. Inc.

• Mylan NV

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

What our reports offer:

• Market share assessments for the regional and country-level segments

• Strategic recommendations for the new entrants

• Covers market data for 2019, 2020, until 2024

• Market trends (drivers, opportunities, threats, challenges, investment opportunities, and recommendations)

• Strategic recommendations in key business segments based on the market estimations

• Competitive landscaping mapping the key common trends

• Company profiling with detailed strategies, financials, and recent developments

• Supply chain trends mapping the latest technological advancements

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio’s in-depth research has direct and indirect COVID-19 impacted market research reports.

Subscribe to World-Class Market Intelligence and gain instant access to 17,000+ market research reports and connect with expert analysts

Key Topics Covered:

Executive Summary

Market Landscape

• Market ecosystem

• Market characteristics

• Value chain analysis

Market Sizing

• Market definition

• Market segment analysis

• Market size 2019

• Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

• Five forces summary

• Bargaining power of buyers

• Bargaining power of suppliers

• Threat of new entrants

• Threat of substitutes

• Threat of rivalry

• Market condition

Market Segmentation by Type

• Market segments

• Comparison by Type

• Herpes zoster - Market size and forecast 2019-2024

• Herpes simplex - Market size and forecast 2019-2024

• Market opportunity by Type

Customer Landscape

Geographic Landscape

• Geographic segmentation

• Geographic comparison

• North America - Market size and forecast 2019-2024

• Europe - Market size and forecast 2019-2024

• Asia - Market size and forecast 2019-2024

• ROW - Market size and forecast 2019-2024

• Key leading countries

• Market opportunity by geography

• Market drivers

• Market challenges

• Market trends

Vendor Landscape

• Competitive Scenario

• Vendor landscape

• Landscape disruption

Vendor Analysis

• Vendors covered

• Market positioning of vendors

• Bausch Health Companies Inc.

• Cipla Inc.

• Eli Lilly and Co.

• Gilead Sciences Inc.

• GlaxoSmithKline Plc

• Maruho Co. Ltd.

• Merck & Co. Inc.

• Mylan NV

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

Appendix

• Scope of the report

• Currency conversion rates for US$

• Research methodology

• List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005053/en/

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/